Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

Cell Cycle

Volumn 11, Issue 20, 2012, Pages 3837-3850

  Oplustilova, Lenka ^a,b   Wolanin, Kamila ^a   Mistrik, Martin ^c   Korinkova, Gabriela ^c   Simkova, Dana ^c   Bouchal, Jan ^c   Lenobel, Rene ^c   Bartkova, Jirina ^a   Lau, Alan ^b   O'Connor, Mark J ^b   Lukas, Jiri ^a,d   Bartek, Jiri ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b ASTRAZENECA   (United Kingdom)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d University of Copenhagen   (Denmark)

Author keywords

53BP1; BRCA1; Cancer treatment; DNA damage response; MRN complex; p53; PARP 1 inhibitor; PARsylation; Predictive biomarkers; Synthetic lethality or viability

Indexed keywords

EID: 84868015370     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22026     Document Type: Article

References (53)

1. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816-24; PMID:18066095; http://dx.doi.org/10.1038/sj.onc.1210879. (Pubitemid 350242461)
2. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481:287-94; PMID:22258607; http://dx.doi.org/10.1038/nature10760.
3. Jackson S P, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/ nature08467.
4. Blagosklonny M V. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011;2:1352-67; PMID:22267462.
5. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28; PMID:16829982; http://dx.doi.org/10.1038/nrm1963. (Pubitemid 44036457)
6. Plummer ER. Inhibition of poly (ADP-ribose) poly-merase in cancer. Curr Opin Pharmacol 2006;6:364-8; PMID:16753340; http://dx.doi.org/10.1016/j. coph.2006.02.004. (Pubitemid 44040837)
7. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5:387-93; PMID:21821475; http://dx.doi.org/10.1016/j. molonc.2011.07.001.
8. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74; PMID:11357144; http://dx.doi.org/10.1038/35077232. (Pubitemid 32467046)
9. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) poly-merase. Nature 2005;434:913-7; PMID:15829966; http://dx.doi.org/10.1038/ nature03443. (Pubitemid 40559005)
10. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445. (Pubitemid 40559006)
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34; PMID:19553641; http://dx.doi.org/10. 1056/NEJMoa0900212.
12. Gagné J P, Isabelle M, Lo KS, Bourassa S, Hendzel MJ, Dawson VL, et al. Proteome-wide identification of poly (ADP-ribose) binding proteins and poly (ADP-ribose)-associated protein complexes. Nucleic Acids Res 2008;36:6959-76; PMID:18981049; http://dx.doi.org/10.1093/nar/gkn771.
13. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011;13:1161-9; PMID:21968989; http://dx.doi.org/10.1038/ncb2344.
14. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol 2007;85:509-20; PMID:17713585; http://dx.doi.org/10.1139/O07-069. (Pubitemid 47518045)
15. Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 2008;283:1197-208; PMID:18025084; http://dx.doi.org/10.1074/jbc. M706734200.
16. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472. CAN-06-0140. (Pubitemid 44299177)
17. Höglund A, Strömvall K, Li Y, Forshell L P, Nilsson JA. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle 2011;10:3598-607; PMID:22030621; http://dx.doi.org/10.4161/cc.10.20.17887.
18. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011;10:1192-9; PMID:21487248; http://dx.doi.org/10.4161/ cc.10.8.15273.
19. Michalak EM, Jonkers J. Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. J Mammary Gland Biol Neoplasia 2011;16:41-50; PMID:21331759; http://dx.doi.org/10.1007/s10911-011-9199-z.
20. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008;7:2010-9; PMID:18832051; http://dx.doi.org/10.1016/j.dnarep. 2008.08.014.
21. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23; PMID:15549093; http://dx.doi.org/10.1038/nature03097. (Pubitemid 39551659)
22. Gallmeier E, Kern SE. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly (ADP-ribose) polymerase inhibition. Cancer Biol Ther 2005;4:703-6; PMID:16082177; http://dx.doi.org/10. 4161/cbt.4.7.1909. (Pubitemid 41351166)
23. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005;4:934-6; PMID:16251802; http://dx.doi.org/10.4161/cbt.4.9.2141. (Pubitemid 41598586)
24. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S, Meuth M. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant-negative manner. Mol Biol Cell 2008;19:1693-705; PMID:18256278; http://dx.doi.org/10.1091/mbc. E07-09-0975. (Pubitemid 351805121)
25. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296-316; PMID:19383352; http://dx.doi.org/10.1016/j. molonc.2008.09.007.
26. Yagi K, Kunitomo K, Ii K, Tashiro S. Relationship of P-glycoprotein and p53 protein to chemosensitivity in colorectal cancer. Int J Clin Oncol 1997;2:81-91; http://dx.doi.org/10.1007/BF02488878. (Pubitemid 127730546)
27. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105:17079-84; PMID:18971340; http://dx.doi.org/10.1073/pnas. 0806092105.
28. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, et al. Poly (ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-5; PMID:19383921; http://dx.doi.org/ 10.1158/0008-5472. CAN-08-2388.
29. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300; PMID:9331090. (Pubitemid 27413438)
30. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2010;16:6159-68; PMID:20802015; http://dx.doi.org/10.1158/1078-0432. CCR-10-1027.
31. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95; PMID:20453858; http://dx.doi.org/10.1038/nsmb.1831.
32. Bunting SF, Callén E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54; PMID:20362325; http://dx.doi.org/10.1016/j. cell.2010.03.012.
33. Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007;26:7414-22; PMID:17546051; http://dx.doi.org/10.1038/sj.onc.1210553. (Pubitemid 350158716)
34. Bauzon F, Zhu L. Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle 2010;9:2118-23; PMID:20505340; http://dx.doi.org/10.4161/cc.9.11.11726.
35. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev 2007;16:2024-32; PMID:17932350; http://dx.doi.org/10.1158/1055-9965. EPI-07-0116.
36. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54; PMID:11850399; http://dx.doi.org/10.1093/embo-reports/kvf044. (Pubitemid 34269518)
37. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001;37:69-82; PMID:11164721; http://dx.doi.org/10.1016/S1040- 8428 (00) 00110-4. (Pubitemid 32063319)
38. Testa U, Pasquini L, Petrucci E. In vitro assays of tumor chemosensitivity and chemoresistance. Drugs Future 2004;29:1035-42; http://dx.doi.org/10.1358/dof.2004.029.10.863394. (Pubitemid 40051091)
39. Hatok J, Babusikova E, Matakova T, Mistuna D, Dobrota D, Racay P. In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 2009;9:1-7; PMID:18818983; http://dx.doi.org/10.1007/s10238-008-0011-3.
40. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) poly-merase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001;84:106-12; PMID:11139322; http://dx.doi.org/10.1054/bjoc.2000.1555. (Pubitemid 32102513)
41. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105:1114-22; PMID:21989215; http://dx.doi.org/10. 1038/bjc.2011.382.
42. Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al. Poly (ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011;10:4074-82; PMID:22101337; http://dx.doi.org/10.4161/cc.10.23.18170.
43. Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010;1:606-19; PMID:21317456.
44. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011;2:984-96; PMID:22184287.
45. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70; PMID:15829956; http://dx.doi.org/10.1038/ nature03482. (Pubitemid 40558993)
46. Guirouilh-Barbat JK, Wilhelm T, Lopez BS. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010;1:691-9; PMID:21321378.
47. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type-and insult-dependent manner and follow expression of p16 (ink4a). Cell Cycle 2011;10:457-68; PMID:21248468; http://dx.doi.org/10.4161/cc.10.3.14707.
48. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly (ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010;70:5389-98; PMID:20551068; http://dx.doi.org/10.1158/0008-5472. CAN-09-4716.
49. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose) poly-merase inhibitors. Clin Cancer Res 2010;16:2344-51; PMID:20371688; http://dx.doi.org/10.1158/1078-0432. CCR-09-2758.
50. Aagaard L, Lukas J, Bartkova J, Kjerulff A-A, Strauss M, Bartek J. Aberrations of p16Ink4 and retinoblasto-ma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995;61:115-20; PMID:7705923; http://dx.doi.org/10.1002/ijc.2910610120.
51. Horejsí Z, Falck J, Bakkenist CJ, Kastan MB, Lukas J, Bartek J. Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene 2004;23:3122-7; PMID:15048089; http://dx.doi.org/10.1038/sj.onc.1207447. (Pubitemid 38648203)
52. Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, et al. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle 2010;9:3085-99; PMID:20699642; http://dx.doi.org/10.4161/cc.9.15.12521.
53. Moudry P, Lukas C, Macurek L, Hanzlikova H, Hodny Z, Lukas J, et al. Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle 2012;11:1573-82; PMID:22456334; http://dx.doi.org/10.4161/cc. 19978.